Cargando…

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2 diabetes was demonstrated in the LEADER (ClinicalTrials.gov: NCT01179048) and SUSTAIN 6 (ClinicalTrials.gov: NCT01720446) cardiovascular outcome trials. This post hoc analysis assessed the impact of diabetes durat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Subodh, Bain, Stephen C., Monk Fries, Tea, Mazer, C. David, Nauck, Michael A., Pratley, Richard E., Rasmussen, Søren, Saevereid, Hans A., Zinman, Bernard, Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619033/ https://www.ncbi.nlm.nih.gov/pubmed/30851070 http://dx.doi.org/10.1111/dom.13698

Ejemplares similares

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
por: Nauck, Michael A., et al.
Publicado: (2020)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
por: Nauck, Michael A, et al.
Publicado: (2018)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
por: Husain, Mansoor, et al.
Publicado: (2022)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
por: Husain, Mansoor, et al.
Publicado: (2020)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial
por: Tack, Cees J., et al.
Publicado: (2019)

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
por: Alsugair, Hassan A., et al.
Publicado: (2021)

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
por: Strain, W. David, et al.
Publicado: (2022)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
por: Rossing, Peter, et al.
Publicado: (2023)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Semaglutide single‐dose pen‐injector: Post hoc analysis of summative usability testing for weight management
por: Klonoff, David C., et al.
Publicado: (2021)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
por: Pratley, Richard E., et al.
Publicado: (2019)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019)

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
por: Steinberg, William M., et al.
Publicado: (2014)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fmocmqm6fro8tm0e7q48iueoce